Aurora kinase inhibitor patents and agents in clinical testing: An update (2011-2013)

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 9, 2014, Pages 1021-1038

  Cheung, Chun Hei Antonio ^a   Sarvagalla, Sailu ^b   Lee, Jane Ying Chieh ^a   Huang, Yi Chun ^a   Coumar, Mohane Selvaraj ^b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b PONDICHERRY UNIVERSITY   (India)

Author keywords

AMG 900 and KW 2449; AT 9283; Aurora kinase inhibitor; AZD1152; CYC116; ENMD 2076; GSK1070916; MLN8054; MLN8237; PF 3814735; PHA739358; R763; SNS 314; VX 680 MK0457; VX 689 MK 5108

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; ALISERTIB; AMG 900; AURORA KINASE INHIBITOR; BARASERTIB; CENISERTIB; CYC 116; DANUSERTIB; ENMD 2076; GSK 1070916; MK 0475; MK 5108; MSC 1992371A; PF 3814735; SNS 314; TOZASERTIB; UNCLASSIFIED DRUG; VX 689; [4 [2 (1H INDAZOL 3 YL)VINYL]PHENYL](1 PIPERAZINYL)METHANONE; ANTINEOPLASTIC AGENT; AURORA KINASE; PROTEIN KINASE INHIBITOR;

CLINICAL TRIAL (TOPIC); DRUG DATABASE; DRUG INFORMATION; HUMAN; NONHUMAN; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; ENZYMOLOGY; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; AURORA KINASES; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; NEOPLASMS; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS;

EID: 84906223147     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.931374     Document Type: Review

References (89)

1. Crane R, Gadea B, Littlepage L, et al. Aurora A, meiosis and mitosis. Biol Cell 2004;96:215-29
2. Kollareddy M, Dzubak P, Zheleva D, et al. Aurora kinases: structure, functions and their association with cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008;152:27-33
3. Barr AR, Gergely F. Aurora-A: the maker and breaker of spindle poles. J Cell Sci 2007;120:2987-96
4. Lee CY, Andersen RO, Cabernard C, et al. Drosophila Aurora-A kinase inhibits neuroblast self-renewal by regulating aPKC/Numb cortical polarity and spindle orientation. Genes Dev 2006;20:3464-74
5. Matsuzaki F. Asymmetric division of Drosophila neural stem cells: a basis for neural diversity. Curr Opin Neurobiol 2000;10:38-44
6. Guo M, Jan LY, Jan YN. Control of daughter cell fates during asymmetric division: interaction of Numb and Notch. Neuron 1996;17:27-41
7. Wirtz-Peitz F, Nishimura T, Knoblich JA. Linking cell cycle to asymmetric division: aurora-A phosphorylates the Par complex to regulate Numb localization. Cell 2008;135:161-73
8. Adams RR, Carmena M, Earnshaw WC. Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol 2001;11:49-54
9. Sasai K, Katayama H, Stenoien DL, et al. Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton 2004;59:249-63
10. Kitajima S, Kudo Y, Ogawa I, et al. Constitutive phosphorylation of aurora-A on ser51 induces its stabilization and consequent overexpression in cancer. PLoS One 2007;2:e944
11. Dar AA, Zaika A, Piazuelo MB, et al. Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer 2008;112:1688-98
12. Vischioni B, Oudejans JJ, Vos W, et al. Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther 2006;5:2905-13
13. Fu J, Bian M, Jiang Q, et al. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007;5:1-10
14. Dutta-Simmons J, Zhang Y, Gorgun G, et al. Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. Blood 2009;114:2699-708
15. Ye D, Garcia-Manero G, Kantarjian HM, et al. Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. J Hematop 2009;2:2-8
16. Macarulla T, Ramos FJ, Tabernero J. Aurora kinase family: a new target for anticancer drug. Recent Pat Anticancer Drug Discov 2008;3:114-22
17. Agnese V, Bazan V, Fiorentino FP, et al. The role of Aurora-A inhibitors in cancer therapy. Ann Oncol 2007;18(Suppl 6):vi47-52
18. Dar AA, Goff LW, Majid S, et al. Aurora kinase inhibitors-rising stars in cancer therapeutics? Mol Cancer Ther 2010;9:268-78
19. Karthigeyan D, Prasad SB, Shandilya J, et al. Biology of Aurora A kinase: implications in cancer manifestation and therapy. Med Res Rev 2011;31:757-93
20. Cheung CH, Coumar MS, Hsieh HP, et al. Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs 2009;18:379-98
21. Coumar MS, Cheung CH, Chang JY, et al. Advances in Aurora kinase inhibitor patents. Expert Opin Ther Pat 2009;19:321-56
22. Cheung CH, Coumar MS, Chang JY, et al. Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10). Expert Opin Ther Pat 2011;21:857-84
23. Kollareddy M, Zheleva D, Dzubak P, et al. Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs 2012;30:2411-32
24. Wissing MD, van Diest PJ, van der Wall E, et al. Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer. Expert Opin Investig Drugs 2013;22:635-61
25. Farag SS. The potential role of Aurora kinase inhibitors in haematological malignancies. Br J Haematol 2011;155:561-79
26. Green MR, Woolery JE, Mahadevan D. Update on Aurora kinase targeted therapeutics in oncology. Expert Opin Drug Discov 2011;6:291-307
27. Giles FJ, Swords RT, Nagler A, et al. MK-0457, an Aurora kinase and BCRABL inhibitor, is active in patients with BCR-ABL T315I leukemia. Leukemia 2013;27:113-17
28. Dewerth A, Wonner T, Lieber J, et al. In vitro evaluation of the Aurora kinase inhibitor VX-680 for Hepatoblastoma. Pediatr Surg Int 2012;28:579-89
29. Tavanti E, Sero V, Vella S, et al. Preclinical validation of Aurora kinasestargeting drugs in osteosarcoma. Br J Cancer 2013;109:2607-18
30. Yao R, Zheng J, Zheng W, et al. VX680 suppresses the growth of HepG2 cells and enhances the chemosensitivity to cisplatin. Oncol Lett 2014;7:121-4
31. Schwartz GK, Carvajal RD, Midgley R, et al. Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Invest New Drugs 2013;31:370-80
32. Kantarjian HM, Martinelli G, Jabbour EJ, et al. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. Cancer 2013;119:2611-19
33. Meulenbeld HJ, Bleuse JP, Vinci EM, et al. Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU Int 2013;111:44-52
34. Fraedrich K, Schrader J, Ittrich H, et al. Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model. Clin Cancer Res 2012;18:4621-32
35. Fei F, Lim M, Schmidhuber S, et al. Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib). Mol Cancer 2012;11:42
36. Balabanov S, Gontarewicz A, Keller G, et al. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor danusertib in BCR-ABL-positive cells in vitro. PLoS One 2011;6:e19164
37. Yang Y, Shen Y, Li S, et al. Molecular dynamics and free energy studies on Aurora kinase A and its mutant bound with MLN8054: insight into molecular mechanism of subtype selectivity. Mol Biosyst 2012;8:3049-60
38. Palani S, Patel M, Huck J, et al. Preclinical pharmacokinetic/ pharmacodynamic/efficacy relationships for alisertib, an investigational smallmolecule inhibitor of Aurora A kinase. Cancer Chemother Pharmacol 2013;72:1255-64
39. Kelly K, Shea T, Goy A, et al. Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs 2014;32(3):489-99
40. Hrabakova R, Kollareddy M, Tyleckova J, et al. Cancer cell resistance to aurora kinase inhibitors: identification of novel targets for cancer therapy. J Proteome Res 2013;12:455-69
41. Baldini E, Sorrenti S, D'Armiento E, et al. Effects of the Aurora kinases paninhibitor SNS-314 mesylate on anaplastic thyroid cancer derived cell lines. Clin Ter 2012;163:e307-13
42. Moy C, Oleykowski CA, Plant R, et al. High Chromosome Number in hematological cancer cell lines is a Negative Predictor of Response to the inhibition of Aurora B and C by GSK1070916. J Transl Med 2011;9:110
43. Schoffski P, Jones SF, Dumez H, et al. Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. Eur J Cancer 2011;47:2256-64
44. Hook KE, Garza SJ, Lira ME, et al. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther 2012;11:710-19
45. Matulonis UA, Lee J, Lasonde B, et al. ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. Eur J Cancer 2013;49:121-31
46. Diamond JR, Eckhardt SG, Tan AC, et al. Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models. Clin Cancer Res 2013;19:291-303
47. Arkenau HT, Plummer R, Molife LR, et al. A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann Oncol 2012;23:1307-13
48. Dent SF, Gelmon KA, Chi KN, et al. NCIC CTG IND.181: phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies. Invest New Drugs 2013;31:1522-9
49. Foran J, Ravandi F, Wierda W, et al. A phase I and pharmacodynamic Study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. Clin Lymphoma Myeloma Leuk 2014;14:223-30
50. Raymond E, Alexandre J, Faivre S, et al. A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors. Invest New Drugs 2014;32:94-103
51. Mita M, Gordon M, Rejeb N, et al. A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors. Target Oncol 2013. [Epub ahead of print]
52. Shan W, Akinfenwa PY, Savannah KB, et al. A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma. Clin Cancer Res 2012;18:3352-65
53. Horwacik I, Durbas M, Boratyn E, et al. Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells. Cancer Lett 2013;341:248-64
54. Kalous O, Conklin D, Desai AJ, et al. AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53. Breast Cancer Res Treat 2013;141:397-408
55. Bush TL, Payton M, Heller S, et al. AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models. Mol Cancer Ther 2013;12:2356-66
56. Shiotsu Y, Kiyoi H, Ishikawa Y, et al. KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood 2009;114:1607-17
57. Nguyen T, Dai Y, Attkisson E, et al. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or-resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res 2011;17:3219-32
58. Ambit Biosciences Corp. Aurora kinase compounds and methods of their use. WO2011088045A1; 2011
59. Amgen, Inc. N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4- (4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer. WO2011031842A1; 2011
60. Amgen, Inc. Aurora kinase modulators and method of use. WO07087276A1; 2007
61. Payton M, Bush TL, Chung G, et al. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res 2010;70:9846-54
62. Huang L, Be X, Berry L, et al. In vitro and in vivo pharmacokinetic characterizations of AMG 900, an orally bioavailable small molecule inhibitor of aurora kinases. Xenobiotica 2011;41:400-8
63. Boeringer Ingelheim International GMBH. Anticancer therapy with dual aurora kinase/MEK inhibitors. WO2012095505A1; 2012
64. Boeringer Ingelheim International GMBH. New compounds. WO2010012747A1; 2010
65. Boeringer Ingelheim International GMBH. Anticancer combination therapy. WO2013060872A1; 2013
66. Cancer Research Technology Ltd. Pharmaceutically active compounds. WO2013190319A1; 2013
67. Chroma Therapeutics Ltd. Enzyme inhibitors. WO07072017A2; 2007
68. Chroma Therapeutics Ltd. Imidazopyridine derivatives useful as enzyme inhibitors. WO2009001021A1; 2009
69. Cancer Research Technology Ltd. Imidazopyridines as inhibitors of aurora kinase and/or FLT3. WO2013190320A1; 2013
70. Genosco and Oscotec, Inc. Kinase inhibitors. WO2011053861A1; 2011
71. Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences. Preparation of 2,4-disubstituted thieno [3,2-d]pyrimidine compounds as anticancer agents. CN103242341A; 2013
72. Merck GMBH. Novel bicyclic urea compounds. WO2011017142A1; 2011
73. H. Lee Moffitt Cancer Centre and Research Institute. Aurora kinase inhibitors and methods of making and using thereof. WO2012135641A2; 2012
74. Lawrence HR, Martin MP, Luo Y, et al. Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors. J Med Chem 2012;55:7392-416
75. Nihon University. Selective expression inhibitor for aurora kinase A and aurora kinase B genes. WO2009066774A1; 2009
76. National Health Research Institutes. Pyrazole compounds and thiazole compounds as protein kinase inhibitors. US20120225880A1; 2012
77. Sanofi. Compound Ethyl 8-oxo-9-[3-[(1H-benzimidazol-2-yl)oxy]phenyl]-4,5, 6,7,8,9-hexahydro-2H-pyrrolo[3,4-b] quinoline-3-carboxylate, salt, crystalline form, cocrystal, formulation, processes for preparation, application as medicaments, pharmaceutical compositions and new use particularly as inhibitors of Aurora kinases. WO2012066486A1; 2012
78. Aventis Pharma S.A. 1,4-Dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them. WO07012972A2; 2007
79. Sanofi-Aventis. Anticancer compounds and Phrmacuetical composition contatining the same. WO2010133794A1; 2010
80. Shenzhen Salubris Pharmaceutical Co., Ltd. and Shanghai Institute of Pharmaceutical Industry. Polycyclic quinazolines, preparation thereof, and use thereof. US2011288086A1, WO2011144059A1; 2011
81. S.un Yat Sen University. Preparation of pyrimidine derivatives as aurora kinase inhibitors for treatment of cancer. CN103059002A; 2013
82. Sun Yat Sen University. Application of pyrimidine derivative in preparing drug for prevention, treatment, and/or adjuvant treatment of tumor. CN103191120A; 2013
83. Sun Yat Sen University. Application of pyrimidine derivative in preparing drugs for prevention/treatment/auxiliary treatment of cancer. CN103202843A; 2013
84. Sunshine Lake Pharma Co., Ltd. Substitued pyrimidine derivatives as aurora kinase inhibitor. WO2013143466A1; 2013
85. Feng Y, Chen YT, Sessions H, et al. Bicyclic heteroaryls as kinase inhibitors. WO2011050245A1; 2011
86. Komlodi-Pasztor E, Sackett DL, Fojo AT. Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Clin Cancer Res 2012;18:51-63
87. Bearss DJ. Shining the light on aurora-A kinase as a drug target in pancreatic cancer. Mol Cancer Ther 2011;10:2012
88. Cohen RB, Jones SF, Aggarwal C, et al. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res 2009;15:6694-701
89. US clinical trials database Available from: www.clinicaltrials.gov